查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553533

美国避孕药具市场规模、份额和趋势分析：按产品和细分市场预测（2024-2030）

U.S. Contraceptive Market Size, Share & Trends Analysis Report By Product (Pills, Intrauterine Devices (IUD), Condoms, Vaginal Ring, Subdermal Implants, Injectable), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 113 Pages | 商品交期: 2-10个工作天内

价格

美国避孕市场的成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，美国避孕药具市场规模预计将达到124.6亿美元，2024年至2030年复合年增长率预计为5.20%。

在美国，避孕器具的供应量有所增加，对社会各个方面产生了积极影响，包括妇女的教育、职业机会和贫困水平。现代避孕方法的出现极大地改善了女性的职业前景，并使她们能够获得与男性同等的工资。此外，由于意外怀孕和抚养孩子的经济负担而陷入贫困的妇女人数也减少了。

计划生育服务的合法化和提供有助于减少贫困和改善子孙后代的经济状况。计划生育计画可以改善妇女和儿童的健康状况，并间接支持经济安全。能够控制自己生殖健康的妇女更有可能参与劳动力队伍并为家庭收入做出贡献，从而进一步降低贫困水平。

2023 年 6 月，拜登-哈里斯政府宣布与<官民合作关係>。该倡议旨在解决美国各地女性日益扩大的健康差距问题。拜登-哈里斯政府致力于加强国际计划生育工作，特别是在避孕器使用率低、孕产妇死亡率高的西非。 2023财年将额外拨款1,550万美元，总合8,650万美元，旨在改善九个法语国家的性健康和生殖健康保健。

此外，COVID-19 大流行对美国医疗保健产业产生了重大影响。默克公司等避孕器具製造商报告称，由于医疗保健提供者优先考虑 COVID-19 患者，对避孕植入Nexplanon 的需求有所下降。然而，疫苗接种的增加和 COVID-19 患者负担的减轻导致服用避孕药具的医生就诊次数回升，从而促进了产品需求。由于长效避孕药和非荷尔蒙避孕药的便利性、避孕功效长效且无副作用，预计未来几年对长效避孕药和非荷尔蒙避孕药的需求将会增加。

美国避孕药具市场报告要点：

  • 从产品来看，药丸由于使用方便且容易取得，占据了最大的市场占有率。由于学名药的存在，该国的避孕药具市场竞争非常激烈。
  • 市场上企业的经营受到学名药竞争、行业重组、竞品合併、已上市产品临床试验的新资讯以及竞争对手新产品获得专利的影响。
  • 由于年轻女性希望避免与荷尔蒙避孕药相关的风险，对非荷尔蒙避孕药的需求预计将会增加。新开发的产品，如非荷尔蒙避孕环、隔膜和创新保险套预计将有助于非荷尔蒙产品领域在预测期内的成长。
  • 2024年4月，Opil美国FDA核准了第一个口服避孕药OTC药丸，开始在包括Walgreens、CVS和Walmart在内的大多数零售药局销售。该产品也可在 CVS Pharmacy 应用程式、CVS.com 以及美国各地 7,500 多家 CVS Pharmacy 商店购买。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章 市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场趋势及展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 行业机会
    • 产业挑战
  • 监管和报销框架
  • 管道分析
  • COVID-19 的影响：定性分析
  • 商业环境分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章美国避孕市场：依产品（2018-2030）

  • 美国避孕市场：产品细分仪表板
  • 2023年及2030年产品趋势及市场占有率分析
  • 美国避孕药具市场规模及预测：依产品分类（2018-2030）
  • 丸
    • 丸剂市场（2018-2030）
    • 子宫内避孕器 (IUD)
  • 保险套
    • 安全套市场（2018-2030）
    • 男用保险套
  • 避孕环
    • 避孕环市场（2018-2030）
  • 皮下植入
    • 皮下植入市场（2018-2030）
  • 注射
    • 注射药品市场（2018-2030）
  • 其他的
    • 其他市场（2018-2030）

第五章竞争状况

  • 主要市场参与企业的最新趋势和影响分析
  • 主要交易及策略联盟分析
  • 供应商情况
  • 参与企业概况
  • 财务表现
  • 产品基准
  • 公司分类
  • 公司市场分析
  • 策略规划
  • 公司简介/上市公司
Product Code: GVR-2-68038-702-5

U.S. Contraceptive Market Growth & Trends:

The U.S. contraceptive market size is anticipated to reach USD 12.46 billion by 2030 and is projected to grow at a CAGR of 5.20% from 2024 - 2030, according to a new report by Grand View Research, Inc. The growing availability of contraceptives in the United States has positively influenced various societal aspects, including education, career opportunities, and poverty levels among women. Access to modern contraceptive methods has significantly enhanced women's career prospects, enabling them to earn wages comparable to their male counterparts. In addition, it has resulted in a decrease in the number of women experiencing poverty due to unplanned pregnancies and the financial burdens associated with raising children.

The legalization and access to family planning services have contributed to reducing poverty and improving economic conditions for future generations. Family planning programs have been linked to improved health outcomes for women and children, which indirectly support economic stability. Women who can control their reproductive health are more likely to participate in the workforce and contribute to household income, further reducing poverty levels.

In June 2023, The Biden-Harris Administration launched a new public-private partnership between the U.S. Department of Health and Human Services (HHS) to enhance access to contraception, which is a crucial aspect of reproductive health. This initiative seeks to tackle the increasing disparities in women's health across the United States. The Biden-Harris Administration is committed to enhancing international family planning efforts, particularly in West Africa, where contraceptive use is low and maternal mortality rates are high. An additional USD 15.5 million has been allocated for fiscal year 2023, bringing the total to USD 86.5 million aimed at improving sexual and reproductive health care in nine Francophone countries.

Furthermore, the COVID-19 pandemic has significantly impacted the U.S. healthcare sector. Contraceptive manufacturers, such as Merck & Co., reported a reduction in demand for the contraceptive implant Nexplanon due to the prioritization of COVID-19 patients by healthcare providers. However, an increase in vaccination and reduced burden of COVID-19 patients helped restore the physician office visits for contraceptive administration, in turn contributing to product demand. Demand for long-acting and nonhormonal contraceptives is expected to increase in the coming years due to convenience, long-term protection, and fewer side effects demonstrated by these contraceptives.

U.S. Contraceptive Market Report Highlights:

  • In terms of product, the pills segment held the largest market share owing to the convenience of use and easy availability. The contraceptive pills market in the country is highly competitive due to the presence of generic products.
  • The operations of market players are affected by generic competition, industry consolidation, competitive combination products, new information from clinical trials of marketed products, and patents granted to competitors' new products, among others.
  • The demand for nonhormonal contraceptives in young women is expected to increase as they want to avoid risks associated with hormonal contraceptives. Newly developed products, such as nonhormonal vaginal rings, diaphragms, and innovative condoms, are expected to aid the growth of nonhormonal products segment during the forecast period.
  • In April 2024, the Opill U.S. FDA approved the first oral contraceptive OTC pill, which began selling at most stores in retail pharmacies such as Walgreens, CVS, and Walmart. The product is also offered at CVS Pharmacy app and CVS.com and more than 7,500 CVS Pharmacy stores in the U.S.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Estimates and Forecast Timeline
  • 1.2. Market Definitions
    • 1.2.1. Segment definitions
      • 1.2.1.1. Product
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
      • 1.4.4.1. Details of Primary Research
    • 1.4.5. Research Assumption
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Data Visualization
  • 1.7. Model Details
    • 1.7.1. Approach 1: Commodity flow analysis
    • 1.7.2. Approach 2: Volume Price Analysis
  • 1.8. Objectives
    • 1.8.1. Objective - 1
    • 1.8.2. Objective - 2
  • 1.9. List of Secondary Sources
  • 1.10. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
    • 2.2.1. Product
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
      • 3.3.1.1. Rapid technological advancements
      • 3.3.1.2. Increasing initiatives by social organizations to improve access to condoms
      • 3.3.1.3. Rising publicly funded family planning services
    • 3.3.2. Market Restraint Analysis
      • 3.3.2.1. Increasing geriatric population and rising prevalence of infertility
      • 3.3.2.2. Adverse effects associated with use of contraceptive drugs and devices
    • 3.3.3. Industry Opportunities
    • 3.3.4. Industry Challenges
  • 3.4. Regulatory and Reimbursement Framework
  • 3.5. Pipeline Analysis
  • 3.6. Impact of COVID-19: Qualitative Analysis
  • 3.7. Business Environment Analysis Tools
    • 3.7.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.7.1.1. Supplier power
      • 3.7.1.2. Buyer power
      • 3.7.1.3. Substitution threat
      • 3.7.1.4. Threat of new entrant
      • 3.7.1.5. Competitive rivalry
    • 3.7.2. PESTEL Analysis

Chapter 4. U.S. Contraceptive Market, By Product, 2018 - 2030 (USD Million)

  • 4.1. U.S. Contraceptive Market: Product Segment Dashboard
  • 4.2. Product Movement & Market Share Analysis, 2023 & 2030
  • 4.3. U.S. Contraceptive Market Size & Forecast and Forecasts, By Product, 2018 - 2030 (USD Million)
  • 4.4. Pills
    • 4.4.1. Pills market, 2018 - 2030 (USD Million)
    • 4.4.2. Intrauterine Device (IUD)
      • 4.4.2.1. Intrauterine Device (IUD) market, 2018 - 2030 (USD Million)
      • 4.4.2.2. Hormonal IUD
        • 4.4.2.2.1. Hormonal IUD market, 2018 - 2030 (USD Million)
      • 4.4.2.3. Nonhormonal IUD
        • 4.4.2.3.1. Nonhormonal IUD market, 2018 - 2030 (USD Million)
  • 4.5. Condoms
    • 4.5.1. Condoms market, 2018 - 2030 (USD Million)
    • 4.5.2. Male Condoms
      • 4.5.2.1. Male condoms market, 2018 - 2030 (USD Million)
      • 4.5.2.2. Female condoms
        • 4.5.2.2.1. Female condoms market, 2018 - 2030 (USD Million)
  • 4.6. Vaginal Ring
    • 4.6.1. Vaginal ring market, 2018 - 2030 (USD Million)
  • 4.7. Subdermal Implants
    • 4.7.1. Subdermal implants market, 2018 - 2030 (USD Million)
  • 4.8. Injectable
    • 4.8.1. Injectable market, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Others market, 2018 - 2030 (USD Million)

Chapter 5. Competitive Landscape

  • 5.1. Recent Developments & Impact Analysis, by Key Market Participants
  • 5.2. Major Deals & Strategic Alliances Analysis
    • 5.2.1. Mergers & acquisitions and joint ventures
    • 5.2.2. Licensing & partnership and technology collaborations
  • 5.3. Vendor Landscape
    • 5.3.1. List of Players in the U.S. Contraceptive Market
    • 5.3.2. Company Market Position Analysis
  • 5.4. Participant's overview
  • 5.5. Financial Performance
  • 5.6. Product Benchmarking
  • 5.7. Company Categorization
  • 5.8. Company Market Position Analysis
  • 5.9. Strategy Mapping
    • 5.9.1. Expansion
    • 5.9.2. Acquisition
    • 5.9.3. Collaborations
    • 5.9.4. Others
  • 5.10. Company Profiles/Listing
    • 5.10.1. Church & Dwight Co., Inc.
      • 5.10.1.1. Overview
      • 5.10.1.2. Financial Performance
      • 5.10.1.3. Product Benchmarking
      • 5.10.1.4. Strategic Initiatives
    • 5.10.2. Reckitt Benckiser Group plc
      • 5.10.2.1. Overview
      • 5.10.2.2. Financial Performance
      • 5.10.2.3. Product Benchmarking
      • 5.10.2.4. Strategic Initiatives
    • 5.10.3. Veru, Inc.
      • 5.10.3.1. Overview
      • 5.10.3.2. Financial Performance
      • 5.10.3.3. Product Benchmarking
      • 5.10.3.4. Strategic Initiatives
    • 5.10.4. Organon Group of Companies
      • 5.10.4.1. Overview
      • 5.10.4.2. Financial Performance
      • 5.10.4.3. Product Benchmarking
      • 5.10.4.4. Strategic Initiatives
    • 5.10.5. Pfizer, Inc.
      • 5.10.5.1. Overview
      • 5.10.5.2. Financial Performance
      • 5.10.5.3. Product Benchmarking
      • 5.10.5.4. Strategic Initiatives
    • 5.10.6. Teva Pharmaceutical Industries Ltd.
      • 5.10.6.1. Overview
      • 5.10.6.2. Financial Performance
      • 5.10.6.3. Product Benchmarking
      • 5.10.6.4. Strategic Initiatives
    • 5.10.7. The Cooper Companies, Inc.
      • 5.10.7.1. Overview
      • 5.10.7.2. Financial Performance
      • 5.10.7.3. Product Benchmarking
      • 5.10.7.4. Strategic Initiatives
    • 5.10.8. Mayer Laboratories, Inc.
      • 5.10.8.1. Overview
      • 5.10.8.2. Financial Performance
      • 5.10.8.3. Product Benchmarking
      • 5.10.8.4. Strategic Initiatives
    • 5.10.9. Agile Therapeutics
      • 5.10.9.1. Overview
      • 5.10.9.2. Financial Performance
      • 5.10.9.3. Product Benchmarking
      • 5.10.9.4. Strategic Initiatives
    • 5.10.10. TherapeuticsMD, Inc.
      • 5.10.10.1. Overview
      • 5.10.10.2. Financial Performance
      • 5.10.10.3. Product Benchmarking
      • 5.10.10.4. Strategic Initiatives
    • 5.10.11. Bayer AG
      • 5.10.11.1. Overview
      • 5.10.11.2. Financial Performance
      • 5.10.11.3. Product Benchmarking
      • 5.10.11.4. Strategic Initiatives
    • 5.10.12. Afaxys, Inc.
      • 5.10.12.1. Overview
      • 5.10.12.2. Financial Performance
      • 5.10.12.3. Product Benchmarking
      • 5.10.12.4. Strategic Initiatives
    • 5.10.13. Mithra Pharmaceuticals
      • 5.10.13.1. Overview
      • 5.10.13.2. Financial Performance
      • 5.10.13.3. Product Benchmarking
      • 5.10.13.4. Strategic Initiatives
    • 5.10.14. Abbvie
      • 5.10.14.1. Overview
      • 5.10.14.2. Financial Performance
      • 5.10.14.3. Product Benchmarking
      • 5.10.14.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Contraceptive methods and associated side effects
  • Table 4 Classification of contraceptives by the U.S. FDA
  • Table 5 States that have expanded contraceptive coverage guarantee in the Affordable Care Act
  • Table 6 Types of oral contraceptives, composition, and regimen
  • Table 7 List of intrauterine devices currently available in the U.S.
  • Table 8 Types of male condom variants
  • Table 9 US contraceptive market revenue estimates and forecast, by product, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 U.S. contraceptive market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape
  • Fig. 12 U.S. contraceptive market: Parent market outlook
  • Fig. 13 U.S. contraceptive market dynamics
  • Fig. 14 Market driver relevance analysis (Current & future impact)
  • Fig. 15 Market restraint relevance analysis (Current & future impact)
  • Fig. 16 U.S. contraceptive market: Porter's five forces analysis
  • Fig. 17 U.S. contraceptive market: PESTLE analysis
  • Fig. 18 U.S. contraceptive market: product segment dashboard
  • Fig. 19 U.S. contraceptive market: product market share analysis, 2023 & 2030
  • Fig. 20 Pills market, 2018 - 2030 (USD Million)
  • Fig. 21 Intrauterine Devices (IUD) market, 2018 - 2030 (USD Million)
  • Fig. 22 Hormonal IUD market, 2018 - 2030 (USD Million)
  • Fig. 23 Nonhormonal IUD market, 2018 - 2030 (USD Million)
  • Fig. 24 Condoms market, 2018 - 2030 (USD Million)
  • Fig. 25 Male condoms market, 2018 - 2030 (USD Million)
  • Fig. 26 Female condoms market, 2018 - 2030 (USD Million)
  • Fig. 27 Vaginal ring market, 2018 - 2030 (USD Million)
  • Fig. 28 Subdermal implants market, 2018 - 2030 (USD Million)
  • Fig. 29 Injectable market, 2018 - 2030 (USD Million)
  • Fig. 30 Others market, 2018 - 2030 (USD Million)
  • Fig. 31 Company/competition categorization
  • Fig. 32 Company market position analysis
  • Fig. 33 U.S. contraceptive market: Strategy mapping